Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-2506PO in patients with Parkinson's Disease

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ono Pharmaceutical Co. Ltd

Criteria

Inclusion Criteria:

1. Diagnosis of Parkinson's disease

2. Stage 2 - Stage 4 of revised Hoehn & Yahr severity score

3. Taking L-dopa/DCI without changing dose and regimen

4. Having motor complication

5. Other inclusion criteria as specified in the study protocol

Exclusion Criteria:

1. Previous participation in ONO-2506PO or ONO-2506 protocol

2. Previous brain surgery for Parkinson's disease

3. Presence or history of serious cardiac disease

4. Other exclusion criteria as specified in the study protocol